https://martin-clinic.com/lemon-and-quince-a-natural-treatment-to-reverse-asthma-and-allergies/
1 Like
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2590663/
Mediators Inflamm. 2008; 2008: 496467.
Published online 2008 Nov 30. doi: 10.1155/2008/496467
PMCID: PMC2590663
Citrus/Cydonia Comp. Can Restore the Immunological Balance in Seasonal Allergic Rhinitis-Related Immunological Parameters In Vitro
E. W. Baars 1, 2 * and H. F. J. Savelkoul 3
Abstract
In two in vitro studies, we examined the immunological (pathways of the) effects of Citrus/Cydonia comp. from, respectively, a healthy and an allergic donor; peripheral blood mononuclear cells (PBMCs) were isolated out of peripheral blood and analyzed in vitro after polyclonal stimulation of T-cells. The differentiation capacity and the influence with regard to Th1 (IFN-γ) and Th2 (IL-5) cells were examined. Citrus/Cydonia comp. has a selective effect on the differentiation of T-cells by producing relatively more IL-10 than IL-12. By that, it also seems to have an effect on the induction of regulatory (IL-10 producing) T-cell subsets. It is in vitro capable of neutralizing (to some extent) the changes, characteristic to allergic rhinitis, with regard to the maturation, differentiation, and activity of the immune system. Thus, Citrus/Cydonia comp. can potentially restore the disturbed immune state of rhinitis patients, which essentially could be sufficient to make allergic symptoms disappear permanently.
ISRN Allergy
Volume 2011 (2011), Article ID 836051, 11 pages
Clinical Study
Citrus/Cydonia Compositum Subcutaneous Injections versus Nasal Spray for Seasonal Allergic Rhinitis: A Randomized Controlled Trial on Efficacy and Safety
Erik W. Baars,1 Miek Jong,1 Andreas F. M. Nierop,2 Inge Boers,1 and Huub F. J. Savelkoul3
Abstract
Background. Clinical experiences in vitro and clinical studies have demonstrated the curative potency and safety of Citrus/Cydonia compositum in seasonal allergic rhinitis treatment. Objectives. To compare the efficacy and safety of two routes of administration (nasal spray versus subcutaneous injections). Methodology: Design. a national, randomised, comparative clinical trial with two parallel groups. Participants. 23 patients fulfilled the study requirements. Intervention. after a one- or two-week wash-out period, 23 patients were randomized, to a 6-week treatment period. Outcomes. immunological and symptom severity changes and safety. Immunologic outcome assessments were blinded to group assignment. 23 patients were randomized and from 22/23 patients (11 in each group) blood samples were analyzed before and after treatment. Conclusion. Both routes of administration demonstrate immunological and clinical effects, with larger inflammatory and innate immunological effects of the nasal spray route and larger allergen-specific clinical effects of the subcutaneous route, and are safe.
Mediators of Inflammation
Volume 2012 (2012), Article ID 109829, 10 pages
http://dx.doi.org/10.1155/2012/109829
Research Article
A Comparative In Vitro Study of the Effects of Separate and Combined Products of Citrus e fructibus and Cydonia e fructibus on Immunological Parameters of Seasonal Allergic Rhinitis
E. W. Baars,1 M. C. Jong,1 I. Boers,1 A. F. M. Nierop,2 and H. F. J. Savelkoul3
Abstract
This paper examined the effects of the combined product, Citrus e fructibus/Cydonia e fructibus (Citrus/Cydonia; Citrus and Cydonia: each 0.01 g/mL), and separate products of Citrus (0.01 g/mL) and Cydonia (0.01 g/mL) on the immunological pathways involved in seasonal allergic rhinitis (SAR). Peripheral blood mononuclear cells (PBMCs) from five healthy and five grass pollen-allergic donors were isolated and analyzed in vitro after polyclonal and allergen-specific stimulation of T cells in the presence of the three extracts. The analyses demonstrated acceptable cell survival with no signs of toxicity. Citrus mainly had a selective effect on reducing allergen-specific chronic inflammatory (TNF-α; Citrus compared to Cydonia and Citrus/Cydonia: −87.4 ( ) and −68.0 ( ), resp.) and Th2 pathway activity (IL-5; Citrus compared to Cydonia: −217.8 ( ); while, both Cydonia and Citrus/Cydonia mainly affected the induction of the allergen-specific Th1 pathway (IFN-γ; Cydonia and Citrus/Cydonia compared to Citrus: 3.8 ( ) and 3.0 ( ), resp.). Citrus and Cydonia demonstrated different working mechanisms in the treatment of SAR and the combination product did not demonstrate larger effects than the separate preparations. Further effectiveness and efficacy studies comparing the effects of the products on SAR in vivo are indicated.
1 Like
http://www.sciencedirect.com/science/article/pii/S0944711310004101?via%3Dihub
https://doi.org/10.1016/j.phymed.2010.11.016
Immunomodulatory properties of a lemon-quince preparation (Gencydo®) as an indicator of anti-allergic potency
Carsten Gründemann, Menelaos Papagiannopoulos, Evelyn Lamy, Volker Mersch-Sundermann, Roman Huber
Abstract
Introduction
Gencydo®, a combination of lemon (Citrus limon) juice and aqueous quince (Cydonia oblonga) extract has been used traditionally in anthroposophical medicine for treating patients with allergic rhinitis or asthma. Because there are no reports about the mode of action, we investigated the anti-allergic effects of this preparation in vitro by using cell lines and primary cells in various biological and immunological endpoints.
Materials and methods
The release of soluble mediators from basophilic cells, mast cells and lung epithelial cells, which are essential for the initiation of early- and late-phase allergic reactions, was analyzed in relation to the synthetic anti-allergic drugs azelastine and dexamethasone. In addition, the impact of Gencydo® on the viability and activation of GM-CSF-activated eosinophil granulocytes was investigated.
Results and discussion
Gencydo® reduced the degranulation and histamine release of IgE-activated basophilic cells and mast cells and inhibited the IgE- and PMA/A23187-induced increases in IL-8, TNF-α and GM-CSF production in mast cells. The effects were comparable to that of the used concentration of azelastine and dexamethasone. Furthermore, Gencydo® partially blocked eotaxin release from human bronchial epithelial cells, but has no impact on the viability and activation of GM-CSF-activated eosinophil granulocytes.
In conclusion, these results give a rational base for the topical use of Gencydo® in treatment of allergic disorders through the down regulation of soluble mediators, which are essential for the initiation and maintenance of allergic reactions.
1 Like
Thanks for liking my article! So grateful for the good research of Baars- it means a lot to us over in the US as everyone wants to see some of the science. I have had really good results in tempering asthma in several patients. Such a key remedy from AM.
1 Like